PTC Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 1K
- Market Cap
- $2.7B
- Website
- http://www.ptcbio.com
- Introduction
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants
- First Posted Date
- 2021-05-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 13
- Registration Number
- NCT04903288
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Duke University Hospital, Durham, North Carolina, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 146
- Registration Number
- NCT04577352
- Locations
- 🇨🇦
Centre de Recherche du Centre Hospitalier de l'Université de Montreal (CRCHUM), Montreal, Quebec, Canada
🇩🇪Department of Neurology and Hertie-Institute for Clinical Brain Research German Center of Neurodegenerative Diseases (DZNE), Tuebingen, Germany
🇳🇿CBR Neurogenetic Research Clinic, University of Auckland, Auckland, New Zealand
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 189
- Registration Number
- NCT04439071
- Locations
- 🇺🇸
University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States
🇨🇴Fundación Santa Fe de Bogotá, Bogotá, Colombia
🇧🇪Clinique Saint Pierre, Ottignies, Belgium
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
- First Posted Date
- 2020-05-07
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 68
- Registration Number
- NCT04378075
- Locations
- 🇺🇸
John Hopkins Medicine, Baltimore, Maryland, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
🇺🇸Pediatric Genetics Clinic (Main MGH Hospital), Boston, Massachusetts, United States
A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT04336826
- Locations
- 🇺🇸
Rare Disease Research, LLC, Atlanta, Georgia, United States
A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- PTC Therapeutics
- Registration Number
- NCT04117880
A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT03796637
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA), Los Angeles, California, United States
A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 11
- Registration Number
- NCT03783923
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
🇩🇰Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 33
- Registration Number
- NCT03761069
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸SCRI Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Rochester MC, Rochester, New York, United States
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 41
- Registration Number
- NCT03761095
- Locations
- 🇺🇸
John Hopkins, Baltimore, Maryland, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Washington University Medical Campus, Saint Louis, Missouri, United States